Article ID Journal Published Year Pages File Type
2820575 Genomics 2015 11 Pages PDF
Abstract

•DNA methylation in ovarian cancer differs by histotypes.•There remains much to be learned in ovarian cancer, attention to histology is a key factor to consider.

Survival after a diagnosis of ovarian cancer has not improved, and despite histological differences, treatment is similar for all cases. Understanding the molecular basis for ovarian cancer risk and prognosis is fundamental, and to this end much has been gleaned about genetic changes contributing to risk, and to a lesser extent, survival. There's considerable evidence for genetic differences between the four pathologically defined histological subtypes; however, the contribution of epigenetics is less well documented. In this report, we review alterations in DNA methylation in ovarian cancer, focusing on histological subtypes, and studies examining the roles of methylation in determining therapy response. As epigenetics is making its way into clinical care, we review the application of cell free DNA methylation to ovarian cancer diagnosis and care. Finally, we comment on recurrent limitations in the DNA methylation literature for ovarian cancer, which can and should be addressed to mature this field.

Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Genetics
Authors
, ,